Category Archives: Regions

Why pharmaceuticals could be the prescription for trade warfare that truly hurts America

Source: Maclean’s | June 12, 2018 What began as a trade skirmish over Donald Trump’s imposition of a 10-per-cent tariff on Canadian steel and aluminum is now clearly a trade war. The miasma is only just lifting from the G7 summit in Charlevoix, Que., in which … Continue reading

Posted in Canada, US Trade tools | Leave a comment

South African Cabinet approves new Intellectual Property Policy

Source: Fix the Patent Laws | May 24, 2018 The Fix the Patent Laws Coalition (FTPL) welcomes the news today that the Cabinet of the Government of South Africa has approved the new Intellectual Property (IP) Policy. After nine years of … Continue reading

Posted in Africa, Fix the patent law, IPR policy, Patent, Uncategorized | Leave a comment

Canada-EU Trade Deal Will Cost Canadians Hundreds Of Millions In Extra Drug Costs: PBO It will take longer for generic drugs to reach the market under the terms of CETA.

Source: Huffpost | April 27, 2018 OTTAWA — An extension of drug patent protections in the Canada-EU free trade deal could end up costing Canadians an estimated $392 million a year, and federal coffers up to $270 million more annually, … Continue reading

Posted in Canada, CETA, Drug prices | Leave a comment

Breaking news for access to biological medicines – Brazilian court nixes biological drug eculizumab patent, says more could follow

Source: BioCentury | April 21, 2018 A Brazilian court unanimously ruled Friday to remove patent protection for Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), opening the door for production of biosimilar versions in the country. In a statement, Brazil’s Attorney General Office said … Continue reading

Posted in Access to Medicins, Brazil Patent Reform, Open access, Patent, Regulation | Leave a comment

Moment of truth for global TB response

On Thursday 16 November 2017, Russian president Vladimir Putin told a hall full of health ministers in Moscow that TB is a “serious problem”, and said, “I am confident that the only way we can stand up against this truly global threat … Continue reading

Posted in BRICS, R&D, Tuberculosis (TB), Uncategorized | Leave a comment

BRICS roots for affordable medicines

Public health targets should be placed above trade deals, says J.P. Nadda By Vidya Krishnan, The Hindu | December 17, 2016 Union Health Minister J.P. Nadda has pressed for public health targets to be placed above trade deals. “Trade regimes … Continue reading

Posted in BRICS, TRIPS plus, Uncategorized | Leave a comment

Open Letter to Ambassadors (in India) of RCEP negotiating countries by Delhi Network of Positive People

Open Letter to Ambassadors of RCEP negotiating countries  Member countries Must Consider the Impact of RCEP on Access to Medicines in Developing Countries  Don’t trade our lives away! We are writing to you on behalf of the Delhi Network of … Continue reading

Posted in Data Exclusivity, FTA, Investor state dispute, IPR Enforcement, LDC transition period, Regional Comprehensive Economic Partnership, TRIPS plus, UN General Assembly HLM | Leave a comment